Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| And I feel very optimistic because, as Rick mentioned earlier, that we have overwhelming requests from the KOL around the world, because they learn about other Phase II results and they do believe that this can be a great potentially the new drug therapy for their patient, the first oral therapy |
| I'm pleased to report that 2023 was a successful year for Lumos, led by our announcement of positive top-line results from our OraGrowtH210 and OraGrowtH212 trials of LUM-201 in pediatric growth hormone deficiency |
| We firmly believe that the data set we are submitting to the FDA for upcoming end-of-Phase II meeting provides ample support for a pivotal trial of LUM-201 at the 1.6 mg/kg dose, affirming its potential as a viable alternative to injectable products for appropriately selected moderate PGHD patients |
| We're confident in the distinct advantages offered by LUM-201 for patients with moderate PGHD and I’m enthusiastic about advancing to the next developmental stage for this asset |
| And to conclude, we're absolutely thrilled by the progress of our program to date and by the excitement among the endocrine community regarding the potential for the first oral therapy for PGHD |
| Rick Hawkins Charles, I might add is that, there are a lot of historical precedents here, where we feel confident about this meeting in really an outstanding briefing book |
| The restoration of normal growth, normal pulsatility, normal IGF-1 levels, and then more natural growth that results from that has led to very consistent and durable growth comparing year two to year one, right? We lose only a small, tiny bit, 6% of our AHV compared to a much larger drop off that you see with daily injectable growth hormone |
| That also demonstrates that oral LUM-201 produces a robust and enduring response at the 1.6 mgs mg/kg dose, making use of our Predictive Enrichment Marker or PEM strategy for selecting suitable moderate PGHD patients, thereby further de-risking our Phase III program |
| Duke will continue to advocate for exploration of LUM-201 within the PGHD clinical community, a mission that has already garnered remarkable interest from pediatric endocrinologists globally |
| So we're pretty confident about our meeting with the FDA |
| As many of you are aware, LUM-201 has successfully met all primary and secondary endpoints in both OraGrowtH trials, demonstrating clear proof-of-concept for its efficacy as an oral alternative to daily and weekly injectables for patients with PGHD |
| We expect to present these data in additional analysis at several meetings throughout 2024 to capitalize on the growing interest and excitement in the pediatric endocrine community about LUM-201 as potentially the first oral therapeutic in this population |
| PGHD is a great opportunity, I think, for us to show the effect of the molecule on restoring natural pulsatility |
| We've been on a podium presenting data on numerous endocrine conferences over the past two years and have seen the overwhelming acceptance of and the excitement for oral LUM-201 |
| Now, OraGrowtH210 successfully achieved its pre-specified primary endpoint, validating our Predictive Enrichment Marker or PEM test, while also meeting the secondary endpoint by demonstrating 100% reproducibility of PEM-positive classification |
| It's good we've been active on the podium at all these endocrine meetings around the world |
| Duke's exceptional credentials are widely acknowledged, given his renowned expertise in growth [hormone] (ph) disorders and his current leadership at the Human Growth Foundation among various other distinguished roles in his esteemed career |
| That suggests that LUM-201 is more efficient than exogenous growth hormone to promote growth |
| I think when we go back to the first global Phase III trial, you can see that the number of countries going to increase, the number of sites going to increase because the timeline we want to enroll, we have a goal that we want to complete enrollment within 15 months to 18 months, which is, again, this goal is actually a little bit better than the goal that those previous Phase III trials have been running |
| So it is very important and it will be a very nice package of durable data that we can bring |
| So we're pretty excited to work with this investigator |
| So I think the -- how we view the PEM tests is, it's going to kind of raise our efficiency, right? We're going to be able to bring in subjects that are likely responders to our molecules |
| So I think the data that we've shown about the small subset of kids that we have at 24 months on growth has been very telling |
| And at the appropriate time, I think that we will partner with anyone who's going to -- we believe is going to be a good partner in those markets |
| These findings enable us to design a successful Phase III trial to show non-inferiority against the daily injectable growth hormone comparator arm |
| So, it will be a very -- it will be a good step forward for us when we get through that and we have agreement on the Phase III protocol |
| As a result, we approached this end-of-Phase II meeting with a high level of confidence |
| These data confirm the importance of LUM-2O1's unique mechanism of action to restore the natural physiology of [indiscernible] growth hormone secretion |
| But we have, I think, the data and have done the background research on each one of those indications to make some good decisions shortly |
| Although OraGrowtH210 was not specifically designed to establish non-inferiority, we're pleased to note that the growth outcomes observed in this study are in line with the non-inferiority thresholds seen in recent successful FDA applications |
| Statement |
|---|
| The net loss for the year ended December 31, 2023, was $34 million, compared to a net loss of $31.1 million for the same period in 2022 |
| These data revealed a sustained effect showing a minimal decrease of approximately 6% in annualized height velocity from year one to year two, as opposed to the significant decline of approximately 20% reported for daily recombinant growth hormone in moderate PGHD patients |
Please consider a small donation if you think this website provides you with relevant information